The Benefit of Bariatric Surgery on Histological Features of Metabolic Associated Fatty Liver Disease Assessed Through Noninvasive Methods.
Bariatric surgery
Fibrosis risk scores
Metabolic associated fatty liver disease
Nonalcoholic fatty liver disease
Nonalcoholic steatohepatitis
Noninvasive assessment
Obesity
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
17
11
2021
accepted:
07
06
2022
revised:
07
06
2022
pubmed:
14
6
2022
medline:
14
7
2022
entrez:
13
6
2022
Statut:
ppublish
Résumé
In patients with clinically severe obesity, metabolic associated fatty liver disease (MAFLD) and steatohepatitis are highly prevalent. There is a lack of prospective studies evaluating the impact of bariatric surgery (BS) on MAFLD using both noninvasive and histological criteria. The present study aims to assess the impact of BS on MAFLD using histological and biochemical criteria. This is a prospective study of 52 patients subjected to BS. Noninvasive fibrosis risk scores (NIFRS) along with anthropometric, clinical, and biochemical parameters were recorded pre- and 12 months post-BS. Liver biopsy was obtained in all individuals at baseline (wedge biopsy) and was repeated at 12 months (percutaneous Tru-cut) in those diagnosed with steatohepatitis. The primary outcome was the change in the degree of steatohepatitis and fibrosis. The secondary outcome was the change in scores for hepatocellular ballooning, lobular inflammation, steatosis, and fibrosis. One year after BS, steatohepatitis resolved in core biopsies with no worsening of fibrosis in 95.7% of individuals (n = 21, 95% CI: 87.3-100), and 13 (56.5%) exhibited complete resolution. Of 15 patients with fibrosis at baseline, 13 (86.7%) showed improvement and 12 exhibited fibrosis resolution. The values of transaminases improved, but only gamma glutamyl transferase (GGT) showed statistical significance. Among the NIFRS, NAFLD fibrosis score (NFS) and Hepamet fibrosis score (HFS) showed significant improvement. In the setting it was studied, BS improved or resolved steatohepatitis and fibrosis in patients with obesity. NIFRS, especially NFS and HFS, and levels of GGT could be used as markers of recovery of liver function after BS.
Sections du résumé
BACKGROUND
In patients with clinically severe obesity, metabolic associated fatty liver disease (MAFLD) and steatohepatitis are highly prevalent. There is a lack of prospective studies evaluating the impact of bariatric surgery (BS) on MAFLD using both noninvasive and histological criteria. The present study aims to assess the impact of BS on MAFLD using histological and biochemical criteria.
METHODS
This is a prospective study of 52 patients subjected to BS. Noninvasive fibrosis risk scores (NIFRS) along with anthropometric, clinical, and biochemical parameters were recorded pre- and 12 months post-BS. Liver biopsy was obtained in all individuals at baseline (wedge biopsy) and was repeated at 12 months (percutaneous Tru-cut) in those diagnosed with steatohepatitis. The primary outcome was the change in the degree of steatohepatitis and fibrosis. The secondary outcome was the change in scores for hepatocellular ballooning, lobular inflammation, steatosis, and fibrosis.
RESULTS
One year after BS, steatohepatitis resolved in core biopsies with no worsening of fibrosis in 95.7% of individuals (n = 21, 95% CI: 87.3-100), and 13 (56.5%) exhibited complete resolution. Of 15 patients with fibrosis at baseline, 13 (86.7%) showed improvement and 12 exhibited fibrosis resolution. The values of transaminases improved, but only gamma glutamyl transferase (GGT) showed statistical significance. Among the NIFRS, NAFLD fibrosis score (NFS) and Hepamet fibrosis score (HFS) showed significant improvement.
CONCLUSIONS
In the setting it was studied, BS improved or resolved steatohepatitis and fibrosis in patients with obesity. NIFRS, especially NFS and HFS, and levels of GGT could be used as markers of recovery of liver function after BS.
Identifiants
pubmed: 35697996
doi: 10.1007/s11695-022-06153-2
pii: 10.1007/s11695-022-06153-2
doi:
Substances chimiques
gamma-Glutamyltransferase
EC 2.3.2.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2682-2695Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
doi: 10.1002/hep.28431
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57.
doi: 10.1002/hep.29367
Katsiki N, Perez-Martinez P, Anagnostis P, et al. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome? Curr Vasc Pharmacol [Internet]. 2018;16:219–27. Available from: http://www.eurekaselect.com/153468/article
Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol [Internet]. Springer US; 2019;16:377–86. Available from: https://doi.org/10.1038/s41575-019-0144-8
Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45:600–6.
doi: 10.1016/j.jhep.2006.06.013
Rinella ME, Tacke F, Sanyal AJ, et al. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol [Internet]. the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver; 2019;71:823–33. Available from: https://doi.org/10.1016/j.jhep.2019.04.019
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-378.e5.
doi: 10.1053/j.gastro.2015.04.005
Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol [Internet]. 2006;4:639–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16630771
Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679–90.
doi: 10.1016/S0140-6736(15)00803-X
Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113–24.
doi: 10.1056/NEJMoa2028395
Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of non-alcoholic steatohepatitis in morbidly obese patients. Gastroenterology [Internet]. Elsevier, Inc; 2015;149:1–10. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0016508515005703
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA [Internet]. 2004;292:1724–37. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15479938
Ziogas IA, Zapsalis K, Giannis D, et al. Metabolic syndrome and liver disease in the era of bariatric surgery: what you need to know! World J Hepatol [Internet]. 2020;12:709–21. Available from: https://www.wjgnet.com/1948-5182/full/v12/i10/709.htm
Lee Y, Doumouras AG, Yu J, et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:1040-1060.e11.
doi: 10.1016/j.cgh.2018.10.017
Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. Elsevier Inc.; 2019;15:502–11.
de Brito e Silva MB, Tustumi F, de Miranda Neto AA, et al. Gastric bypass compared with sleeve gastrectomy for nonalcoholic fatty liver disease: a systematic review and meta-analysis. Obes Surg. 2021;31:2762–72.
Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology [Internet]. Elsevier, Inc; 2019;156:1264–1281.e4. Available from: https://doi.org/10.1053/j.gastro.2018.12.036
Kruger FC, Daniels CR, Kidd M, et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. South African Med J. 2011;101:477–80.
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.
doi: 10.1002/hep.21178
Forns X, Ampurdanès S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986–92.
pubmed: 12297848
Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–54.
doi: 10.1002/hep.21496
Harrison SA, Oliver D, Arnold HL, et al. Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–7.
doi: 10.1136/gut.2007.146019
Ampuero J, Pais R, Aller R, et al. Development and validation of Hepamet Fibrosis Scoring system—a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis. Clin Gastroenterol Hepatol [Internet]. Elsevier, Inc; 2019; Available from: https://doi.org/10.1016/j.cgh.2019.05.051
Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117–23.
doi: 10.1016/S0016-5085(00)70364-7
Cazzo E, Jimenez LS, Pareja JC, et al. Effect of Roux-en-y gastric bypass on nonalcoholic fatty liver disease evaluated through NAFLD fibrosis score: a prospective study. Obes Surg. 2015;25:982–5.
doi: 10.1007/s11695-014-1489-2
Yeo SC, Ong WM, Cheng KSA, et al. Weight loss after bariatric surgery predicts an improvement in the non-alcoholic fatty liver disease (NAFLD) fibrosis score. Obes Surg. 2019;29:1295–300.
doi: 10.1007/s11695-018-03676-5
Jimenez LS, Mendonça Chaim FH, Mendonça Chaim FD, et al. Impact of weight regain on the evolution of non-alcoholic fatty liver disease after Roux-en-Y gastric bypass: a 3-year follow-up. Obes Surg. 2018;28:3131–5.
doi: 10.1007/s11695-018-3286-9
Nickel F, Tapking C, Benner L, et al. Bariatric surgery as an efficient treatment for non-alcoholic fatty liver disease in a prospective study with 1-year follow-up: BariScan study. Obes Surg. 2018;28:1342–50.
doi: 10.1007/s11695-017-3012-z
Rubio MA, Salas-Salvadó J, Barbany M, et al. Consenso Seedo 2007 Para La Evaluación Del Sobrepeso Y La Obesidad Y El Establecimiento De Criterios De Intervención Terapéutica. Rev Española Obes [Internet]. 2007;7–48. Available from: http://medcontent.metapress.com/index/A65RM03P4874243N.pdf
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.
doi: 10.1007/BF00280883
Mathurin P, Gonzalez F, Kerdraon O, et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology. 2006;130:1617–24.
doi: 10.1053/j.gastro.2006.02.024
Kleiner DE, Berk PD, Hsu JY, et al. Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) study. Semin Liver Dis. 2014;34:98–107.
doi: 10.1055/s-0034-1371083
Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49:1017–44.
doi: 10.1002/hep.22742
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.
doi: 10.1002/hep.20701
Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751–9.
doi: 10.1002/hep.25889
Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39:861–77.
doi: 10.2337/dc16-0236
Deitel M, Gawdat K, Melissas J. Reporting weight loss 2007. Obes Surg [Internet]. 2007;17:565–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17658011
Mummadi RR, Kasturi KS, Chennareddygari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol [Internet]. AGA Institute; 2008;6:1396–402. Available from: https://doi.org/10.1016/j.cgh.2008.08.012
Bower G, Toma T, Harling L, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015;25:2280–9.
doi: 10.1007/s11695-015-1691-x
Perysinakis I, Pappis HC, Margaris E. Current controversies in metabolic surgery for nonalcoholic fatty liver disease. Obes Surg. 2019;29:1058–67.
doi: 10.1007/s11695-019-03705-x
Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology [Internet]. AGA Institute American Gastroenterological Association; 2009;137:532–40. Available from: https://doi.org/10.1053/j.gastro.2009.04.052
Ashrafian H, Athanasiou T, Li JV, et al. Diabetes resolution and hyperinsulinaemia after metabolic Roux-en-Y gastric bypass. Obes Rev. 2011;12:257–72.
doi: 10.1111/j.1467-789X.2010.00802.x
Bower G, Athanasiou T, Isla AM, et al. Bariatric surgery and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27:755–68.
doi: 10.1097/MEG.0000000000000375
Keitel V, Häussinger D. Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin Res Hepatol Gastroenterol [Internet]. Elsevier Masson SAS; 2012;36:412–9. Available from: https://doi.org/10.1016/j.clinre.2012.03.008
Verma S, Jensen D, Hart J, et al. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013;33:1398–405.
doi: 10.1111/liv.12226
Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–92.
doi: 10.1053/jhep.2003.50229
Baldwin D, Chennakesavalu M, Gangemi A. Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria. Surg Obes Relat Dis [Internet]. Elsevier Inc.; 2019;15:2123–30. Available from: https://doi.org/10.1016/j.soard.2019.09.060
Meneses D, Olveira A, Corripio R, et al. Prevalence and predictors of non-alcoholic steatohepatitis in patients with morbid obesity. Endocrinol Diabetes y Nutr. 2021
Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol [Internet]. Nature Publishing Group; 2017;112:18–35. Available from: https://doi.org/10.1038/ajg.2016.517
Udelsman BV, Corey K, Hutter MM, et al. Use of noninvasive scores for advanced liver fibrosis can guide the need for hepatic biopsy during bariatric procedures. Surg Obes Relat Dis [Internet]. Elsevier Inc.; 2021;17:292–8. Available from: https://doi.org/10.1016/j.soard.2020.09.037
Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology [Internet]. Elsevier, Inc; 2020;159:1290–1301.e5. Available from: https://doi.org/10.1053/j.gastro.2020.06.006
Care D, Suppl SS. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. Diabetes Care. 2020;43:S14–31
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. Circulation [Internet]. 2005;112:2735–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16157765